Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 162 recruiting now early-phase tilt #14 of 28,707 conditions

Colorectal Cancer: early-phase trial registry

162 of 394 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #14 of 28,707 conditions by registered trial count.

394 US clinical trials · 162 currently recruiting · #14 of 28,707 conditions by registered trial count

Colorectal Cancer: 394 US clinical trials tracked, 162 recruiting.

Colorectal Cancer is the subject of 394 registered US clinical trials on ClinicalTrials.gov, 162 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 201 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.

Enrollment posture brief

Registry condition colorectal-cancer

OPEN 162 | RECR 41% | LATE 13 | EARLY 201 | RANK #14 | SPON 22

Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)

Heart Failure41.1%Colorectal Cancer (this)41%Anxiety40.3%Pain28.1%Asthma18.5%
Open-enrollment share among volume-matched conditions near Colorectal Cancer

Colorectal Cancer lists 162 open slots (41% of 394 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Colorectal Cancer is recruiting above its size-band peers.

    162 of 394 indexed trials (41.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Colorectal Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 22 of 394 trials (5.6%). 222 distinct sponsors appear on at least one study for this condition label.

  3. Typical Colorectal Cancer enrolment sits around 132 participants.

    Median target enrolment is 132 among the 382 trials that report a genuine target (sentinel values excluded). 162 of those (42.4%) plan for fewer than 100 participants.

  4. Colorectal Cancer research is mostly interventional.

    323 interventional and 71 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1132Phase 269Phase 310Phase 43

Open and recent trials

394 total, page 1 of 8

RECRUITING 130,000 participants

Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study

VA Office of Research and Development

NCT05994482

RECRUITING 25,000 participants

Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)

Natera

NCT07046585

RECRUITING 12,000 participants

A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation

Universal Diagnostics

NCT06059963

RECRUITING NA 8,946 participants

Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

Dartmouth-Hitchcock Medical Center

NCT05612347

RECRUITING 7,000 participants

Evaluation for NCI Surgery Branch Clinical Research Protocols

National Cancer Institute (NCI)

NCT00001823

RECRUITING 7,000 participants

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Adela

NCT05366881

RECRUITING 6,500 participants

Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance

Universal Diagnostics

NCT07310446

RECRUITING NA 6,000 participants

Community Partnership for Telehealth Solutions to Counter Misinformation and Achieve Equity

University of Arizona

NCT06542835

RECRUITING 5,000 participants

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

Persephone Biosciences

NCT04638751

RECRUITING 5,000 participants

ColoCare Study - Colorectal Cancer Cohort

University of Utah

NCT02328677

RECRUITING 5,000 participants

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients

Vanderbilt University Medical Center

NCT00899626

RECRUITING 3,375 participants

Shield Post-Approval Study Protocol

Guardant Health

NCT06880055

RECRUITING 2,300 participants

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

San Raffaele University

NCT05732623

RECRUITING 2,000 participants

Early Detection of Advanced Adenomas and Colorectal Cancer

City of Hope Medical Center

NCT06342440

RECRUITING 2,000 participants

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

Elephas

NCT07327489

RECRUITING 1,366 participants

Collection of Information to Better Understand Young Onset Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT04489238

RECRUITING 1,250 participants

Urine Metabolites in the Diagnosis of Disease

Luventix

NCT06710067

RECRUITING NA 1,200 participants

A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans

University of Nebraska

NCT05903885

RECRUITING Phase 1 1,130 participants

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Revolution Medicines

NCT06445062

RECRUITING 1,120 participants

Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction

Weill Medical College of Cornell University

NCT06096688

RECRUITING NA 1,020 participants

Video Education With Result Dependent dIsclosure

Dana-Farber Cancer Institute

NCT05225428

RECRUITING NA 1,000 participants

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics

M.D. Anderson Cancer Center

NCT05694559

RECRUITING NA 1,000 participants

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

M.D. Anderson Cancer Center

NCT05649072

RECRUITING 1,000 participants

Preserving Fertility After Colorectal Cancer Study

Andreana Holowatyj, PhD, MSCI

NCT05239338

RECRUITING NA 1,000 participants

mPATH-Cloud for Colorectal Cancer Screening

UNC Lineberger Comprehensive Cancer Center

NCT06441487

RECRUITING NA 880 participants

Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk

Columbia University

NCT05174286

RECRUITING Phase 3 800 participants

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Roswell Park Cancer Institute

NCT06563388

RECRUITING Phase 1 768 participants

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Boehringer Ingelheim

NCT06324357

RECRUITING Phase 1 630 participants

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Eli Lilly and Company

NCT06586515

RECRUITING 620 participants

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

University of Missouri-Columbia

NCT02838836

RECRUITING 600 participants

Liquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNA

City of Hope Medical Center

NCT07224789

RECRUITING Phase 1 575 participants

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines

NCT05919264

RECRUITING Phase 1 534 participants

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Revolution Medicines

NCT06128551

RECRUITING Phase 1 523 participants

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Merus B.V.

NCT03526835

RECRUITING NA 500 participants

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

UNC Lineberger Comprehensive Cancer Center

NCT06896162

RECRUITING Phase 1 474 participants

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

A2 Biotherapeutics

NCT06051695

RECRUITING 470 participants

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Guardant Health

NCT05935384

RECRUITING Phase 2 454 participants

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AstraZeneca

NCT05489211

RECRUITING Phase 1 450 participants

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech

NCT05581004

RECRUITING NA 445 participants

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Memorial Sloan Kettering Cancer Center

NCT04751435

RECRUITING 416 participants

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Elephas

NCT05520099

RECRUITING Phase 1 405 participants

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

ArriVent BioPharma

NCT07066657

RECRUITING Phase 1 403 participants

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Frontier Medicines Corporation

NCT06244771

RECRUITING 400 participants

Early Onset Colorectal Cancer Detection

City of Hope Medical Center

NCT06342401

RECRUITING 400 participants

Stage II/III Colorectal Cancer Recurrence

City of Hope Medical Center

NCT06314958

RECRUITING 400 participants

Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

University of Colorado, Denver

NCT05517811

RECRUITING 400 participants

FITting Non-invasive Tests in Lynch Syndrome Surveillance

University of Chicago

NCT06898996

RECRUITING Phase 1 364 participants

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Astellas Pharma

NCT07094204

RECRUITING Phase 1 336 participants

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

IDEAYA Biosciences

NCT03947385

RECRUITING 320 participants

Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

University of Missouri-Columbia

NCT03551951

Page 1 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 132
Phase 2 69
Phase 3 10
Phase 4 3

Named interventions

Most-linked intervention names on Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cetuximab Drug
15 trials
Oxaliplatin Drug
14 trials
Bevacizumab Drug
11 trials
irinotecan hydrochloride Drug
9 trials
fluorouracil Drug
9 trials
Irinotecan Drug
9 trials
leucovorin calcium Drug
8 trials
Leucovorin Drug
7 trials

US sites by state

Facility locations filed on Colorectal Cancer trials. A trial with sites in several states counts in each.

California 133 trials
New York 100 trials
Texas 98 trials
Florida 86 trials
Massachusetts 64 trials
Pennsylvania 57 trials
Tennessee 53 trials
Michigan 51 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Colorectal Cancer page

394 registered trials, 162 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Cancer condition card totals 394 registered trials; most-linked intervention Cetuximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.